SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed  Pre-A and Pre-A+ financing with a total of approximately $20 million. This Pre-A round is led by Shunxi Fund, followed by Cnfuel Capital, Vinner Therapeutics and existing investors such as Qiming Venture Partners and BioTrack Capital.

上海，2024年4月22日/PRNewswire/--Brise Pharmaceuticals Co.，LTD.（Brise）是一家专门从事急性和慢性疼痛创新治疗的开创性公司，最近完成了Pre-a和Pre-a+融资，总金额约为2000万美元。这一轮A前投资由顺熙基金牵头，其次是Cnfuel Capital、Vinner Therapeutics以及启明风险投资合伙公司和BioTrack Capital等现有投资者。

The Pre-A+ round is exclusively invested by Sherpa Healthcare Partners..

Pre-A+round由Sherpa Healthcare Partners独家投资。

Brise has advanced two molecules to the clinical stage in US and China. The funds raised will be used to advance the company's product pipeline in the preclinical and clinical stages, as well as to further refine and validate the Trigeminovascular System (TVS) biology-based drug development platform and the Dorsal Root Ganglion (DRG) biology-based drug development platform..

Brise在美国和中国已将两种分子推进临床阶段。筹集的资金将用于推进公司在临床前和临床阶段的产品线，以及进一步完善和验证基于三叉神经血管系统（TVS）生物学的药物开发平台和基于背根神经节（DRG）生物学的药物开发平台。

Brise, led by CEO Dr. Guochun Li, stands as a clinical-stage biopharmaceutical company with a singular focus on the development of innovative and highly differentiated analgesic treatments for debilitating pain conditions with large unmet needs, placing a particular emphasis on addressing  migraine, neuropathic and musculoskeletal pain.

Brise由首席执行官李国春博士领导，是一家临床阶段的生物制药公司，专注于开发创新和高度分化的镇痛治疗方法，以满足大量未满足需求的虚弱疼痛状况，特别强调解决偏头痛，神经性和肌肉骨骼疼痛。

The organization's vision is to provide safe, effective, and accessible pain relief solutions for the multitude of patients worldwide grappling with poorly managed pain conditions..

该组织的愿景是为全世界面临管理不善的疼痛状况的众多患者提供安全，有效和可获得的疼痛缓解解决方案。